Node-positive renal cell carcinoma in the absence of distant metastases: Predictors of cancer-specific mortality in a population-based cohort

BJU International

Volumn 110, Issue , 2012, Pages

  Trinh, Quoc Dien ^c   Schmitges, Jan ^c,d   Bianchi, Marco ^c   Sun, Maxine ^c   Shariat, Shahrokh F ^b   Sammon, Jesse ^a   Jeldres, Claudio ^c   Zorn, Kevin ^c   Sukumar, Shyam ^a   Perrotte, Paul ^c   Graefen, Markus ^d   Rogers, Craig G ^a   Peabody, James O ^a   Menon, Mani ^a   Karakiewicz, Pierre I ^c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

prognostic; renal cell carcinoma; stage; survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; REGISTRIES; UNITED STATES; YOUNG ADULT;

EID: 84863556486     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10701.x     Document Type: Article

References (36)

1. Sun M, Thuret R, Abdollah F, et al,. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in north america: a trend analysis. Eur Urol 2011; 59: 135-41
2. Jemal A, Bray F, Center M, Ferlay J,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
3. Pantuck AJ, Zisman A, Belldegrun AS,. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611-23
4. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG,. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006; 175: 864-9
5. Petkovic SD,. An anatomical classification of renal tumors in the adult as a basis for prognosis. J Urol 1959; 81: 618-23
6. Robson CJ, Churchill BM, Anderson W,. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-301
7. Flocks RH, Kadesky MC,. Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol 1958; 79: 196-201
8. Rafla S,. Renal cell carcinoma. Natural history and results of treatment. Cancer 1970; 25: 26-40
9. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF,. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28: 1165-77
10. Giuliani L, Giberti C, Martorana G, Rovida S,. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143: 468-73; discussion 73-4
11. Pantuck AJ, Zisman A, Dorey F, et al,. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003; 169: 2076-83
12. Johnsen JA, Hellsten S,. Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol 1997; 157: 450-3
13. Karakiewicz PI, Trinh QD, Bhojani N, et al,. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007; 51: 1616-24
14. Messing EM,. Node positive renal cell cancer. Who can be helped? Eur Urol 2007; 51: 1477-8
15. Mazumdar M, Glassman JR,. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 2000; 19: 113-32
16. Fuhrman SA, Lasky LC, Limas C,. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63
17. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML,. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 612-24
18. Steiner T, Knels R, Schubert J,. Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol 2004; 46: 327-30
19. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P,. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166: 63-7
20. Sorbellini M, Kattan MW, Snyder ME, et al,. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173: 48-51
21. Patard JJ, Leray E, Cindolo L, et al,. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 2004; 172: 858-62
22. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A,. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090-5; quiz 295
23. Zisman A, Pantuck AJ, Dorey F, et al,. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002; 20: 1368-74
24. Terrone C, Cracco C, Porpiglia F, et al,. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006; 49: 324-31
25. Terrone C, Guercio S, De Luca S, et al,. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 2003; 91: 37-40
26. Joslyn SA, Sirintrapun SJ, Konety BR,. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology 2005; 65: 675-80
27. Crispen PL, Breau RH, Allmer C, et al,. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 2011; 59: 18-23
28. Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM,. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res 1999; 19: 1573-8
29. Capitanio U, Jeldres C, Patard JJ, et al,. Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. BJU Int 2009; 103: 33-7
30. Pizzocaro G, Piva L, Colavita M, et al,. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19: 425-31
31. Messing EM, Manola J, Wilding G, et al,. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214-22
32. Clark JI, Atkins MB, Urba WJ, et al,. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21: 3133-40
33. Atzpodien J, Schmitt E, Gertenbach U, et al,. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92: 843-6
34. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK,. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 2007; 109: 1763-8
35. Kutikov A, Egleston BL, Wong Y-N, Uzzo RG,. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28: 311-7
36. Lin DW, Porter M, Montgomery B,. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer 2009; 115: 2863-71